These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 4042521)

  • 1. Sulindac metabolism: the importance of an intact colon.
    Strong HA; Warner NJ; Renwick AG; George CF
    Clin Pharmacol Ther; 1985 Oct; 38(4):387-93. PubMed ID: 4042521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.
    Sitar DS; Owen JA; MacDougall B; Hunter T; Mitenko PA
    Clin Pharmacol Ther; 1985 Aug; 38(2):228-34. PubMed ID: 4017423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of sulindac and metabolites in plasma and urine by high-performance liquid chromatography.
    Stubbs RJ; Ng LL; Entwistle LA; Bayne WF
    J Chromatogr; 1987 Jan; 413():171-80. PubMed ID: 3558666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibuprofen and sulindac kinetics in alcoholic liver disease.
    Juhl RP; Van Thiel DH; Dittert LW; Albert KS; Smith RB
    Clin Pharmacol Ther; 1983 Jul; 34(1):104-9. PubMed ID: 6861431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary secretion of sulindac and metabolites in man.
    Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE
    Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethyl sulfoxide inhibits bioactivation of sulindac.
    Swanson BN; Boppana VK; Vlasses PH; Rotmensch HH; Ferguson RK
    J Lab Clin Med; 1983 Jul; 102(1):95-101. PubMed ID: 6854139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dimethyl sulfoxide on sulindac disposition in rats.
    Swanson BN; Mojaverian P; Boppana VK; Dudash MR
    Drug Metab Dispos; 1981; 9(6):499-502. PubMed ID: 6120805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
    Duggan DE
    Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A kinetic study of sulindac in the elderly.
    Bayley N; Warne RW; Moulds RF; Bury RW
    Aust N Z J Med; 1987 Feb; 17(1):39-42. PubMed ID: 3476045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enterohepatic circulation of sulindac and metabolites.
    Dujovne CA; Pitterman A; Vincek WC; Dobrinska MR; Davies RO; Duggan DE
    Clin Pharmacol Ther; 1983 Feb; 33(2):172-7. PubMed ID: 6822030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reduction of sulphinpyrazone and sulindac by intestinal bacteria.
    Strong HA; Renwick AG; George CF; Liu YF; Hill MJ
    Xenobiotica; 1987 Jun; 17(6):685-96. PubMed ID: 3630204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of sulindac metabolism by dimethyl sulfoxide in the rat.
    Swanson BN; Mojaverian P; Boppana VK
    J Toxicol Environ Health; 1983; 12(2-3):213-22. PubMed ID: 6655731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Individual variability in concentrations of urinary sulindac sulfide.
    Brandli DW; Sarkissian E; Ng SC; Paulus HE
    Clin Pharmacol Ther; 1991 Dec; 50(6):650-5. PubMed ID: 1752108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulindac disposition when given once and twice daily.
    Swanson BN; Boppana VK; Vlasses PH; Holmes GI; Monsell K; Ferguson RK
    Clin Pharmacol Ther; 1982 Sep; 32(3):397-403. PubMed ID: 7049504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of sulindac and its metabolites in human plasma and urine by high-performance liquid chromatography.
    Swanson BN; Boppana VK
    J Chromatogr; 1981 Sep; 225(1):123-30. PubMed ID: 7298740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cholestyramine resin administration on single dose sulindac pharmacokinetics.
    Malloy MJ; Ravis WR; Pennell AT; Hagan DR; Betagari S; Doshi DH
    Int J Clin Pharmacol Ther; 1994 Jun; 32(6):286-9. PubMed ID: 7921528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.